文献速递外周动脉疾病

脂肪酸结合蛋白4在外周动脉疾病中具有预后价值

Fatty acid binding protein 4 has prognostic value in peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2023-06-15

前瞻性病例对照研究随访3年,检测569例外周动脉疾病(PAD)患者和279例无PAD者的基线血清脂肪酸结合蛋白4(FABP4)浓度。FABP4较高与3年主要不良肢体事件(MALE)和PAD状态恶化显著相关,Kaplan-Meier分析显示高FABP4组无MALE生存率75% vs 88%。FABP4有助于对患者进行风险分层以进一步血管评估和管理。

要点

  • FABP4较高与3年MALE风险相关(校正HR 1.18,95%CI 1.03-1.27,P=.022)。
  • FABP4较高与3年PAD状态恶化风险相关(校正HR 1.17,95%CI 1.12-1.28,P<.001)。
  • 高FABP4组3年无MALE生存率75% vs 88%(log rank=22.6,P<.001)。

核心结论

  • 血清FABP4浓度较高的个体更可能发生PAD相关不良肢体事件。
  • FABP4在风险分层方面具有预后价值,可用于进一步血管评估和管理。

研究设计与样本

  • 前瞻性病例对照研究,随访3年。
  • 基线测量PAD患者(n=569)和无PAD者(n=279)的血清FABP4浓度。
  • 主要结局为MALE(血管干预或大截肢的复合终点),次要结局为PAD状态恶化(踝肱指数下降≥0.15)。
  • 采用Kaplan-Meier分析和校正基线特征的Cox比例风险分析评估FABP4的预测能力。

主要发现

  • 研究期间MALE和PAD状态恶化分别发生于162例(19%)和92例(11%)患者。
  • FABP4较高与3年MALE显著相关:未校正HR 1.19(95%CI 1.04-1.27),校正HR 1.18(95%CI 1.03-1.27),P=.022。
  • FABP4较高与3年PAD状态恶化显著相关:未校正HR 1.18(95%CI 1.13-1.31),校正HR 1.17(95%CI 1.12-1.28),P<.001。
  • 3年Kaplan-Meier分析显示高FABP4组无MALE生存率75% vs 88%(log rank=22.6,P<.001),无血管干预生存率77% vs 89%(log rank=20.8,P<.001),无PAD状态恶化生存率87% vs 91%(log rank=6.16,P=.013)。

临床怎么用

  • 作者认为FABP4具有预后价值,可用于对患者进行风险分层以进一步血管评估和管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Peripheral artery disease (PAD) remains undertreated, despite its association with major amputation and mortality. This is partly due to a lack of available disease biomarkers. The intracellular protein fatty acid binding protein 4 (FABP4) is implicated in diabetes, obesity, and metabolic syndrome. Given that these risk factors are strong contributors to vascular disease, we assessed the prognostic ability of FABP4 in predicting PAD-related adverse limb events. METHODS: This was a prospective case-control study with 3 years of follow-up. Baseline serum FABP4 concentrations were measured in patients with PAD (n = 569) and without PAD (n = 279). The primary outcome was major adverse limb event (MALE; defined as a composite of vascular intervention or major amputation). The secondary outcome was worsening PAD status (drop in ankle-brachial index ≥0.15). Kaplan-Meier and Cox proportional hazards analyses adjusted for baseline characteristics were conducted to assess the ability of FABP4 to predict MALE and worsening PAD status. RESULTS: Patients with PAD were older and more likely to have cardiovascular risk factors compared with those without PAD. Over the study period, MALE and worsening PAD status occurred in 162 (19%) and 92 (11%) patients, respectively. Higher FABP4 levels were significantly associated with 3-year MALE (unadjusted hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.04-1.27; adjusted HR, 1.18; 95% CI, 1.03-1.27; P = .022) and worsening PAD status (unadjusted HR, 1.18; 95% CI, 1.13-1.31; adjusted HR, 1.17; 95% CI, 1.12-1.28; P < .001). Three-year Kaplan-Meier survival analysis demonstrated that patients with high FABP4 levels had a decreased freedom from MALE (75% vs 88%; log rank = 22.6; P < .001), vascular intervention (77% vs 89%; log rank = 20.8; P < .001), and worsening PAD status (87% vs 91%; log rank = 6.16; P = .013). CONCLUSIONS: Individuals with higher serum concentrations of FABP4 are more likely to develop PAD-related adverse limb events. FABP4 has prognostic value in risk-stratifying patients for further vascular evaluation and management.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Li B, Zamzam A, Syed MH, et al. Fatty acid binding protein 4 has prognostic value in peripheral artery disease. J Vasc Surg. 2023. PMID: 37318430. doi:10.1016/j.jvs.2023.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。